TNFRSF4 and neoplasm: By targeting OX-40 with agonistic antibodies, this study demonstrates the ability to potentiate anti-tumor immunity while reducing the suppressive function of Tregs, thus shifting the immune landscape toward a more pro-inflammatory and tumor-eliminating state.